Neurocrine Biosciences Unveils New Findings on INGREZZA® vs AUSTEDO XR for Movement Disorders

Introduction

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has recently made headlines with the presentation of pivotal head-to-head data comparing the efficacy of its product, INGREZZA® (valbenazine), against AUSTEDO XR (deutetrabenazine) in managing conditions linked to involuntary movements such as tardive dyskinesia and chorea associated with Huntington's disease.

Study Overview

At the American College of Neuropsychopharmacology's 64th Annual Meeting, held from January 12-15, 2026, in the Bahamas, researchers presented findings that could reshape how these movement disorders are treated. The focus was on different doses of each medication and their impact on vesicular monoamine transporter 2 (VMAT2) target occupancy—an essential indicator of how effectively these drugs can engage with their intended target.

Results

The study utilized cutting-edge positron emission tomography (PET) imaging technology to compare the VMAT2 occupancy levels of both treatments. Participants received either INGREZZA in doses of 40 mg or 80 mg or AUSTEDO XR in doses of 24 mg or 48 mg. Notably, the results revealed that INGREZZA achieved an impressive VMAT2 target occupancy of about 76.5% for the lower dosage and an astounding 92% for the higher one. In contrast, AUSTEDO XR only reached 38.3% at therapeutic doses, indicating that INGREZZA provides nearly double the occupancy compared to its competitor.

Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine, highlighted the implications of these findings, stating, "The significantly higher VMAT2 occupancy observed with INGREZZA adds to the already established differences between these VMAT2 inhibitors in pharmacologic and clinical profiles. Additionally, this high occupancy may contribute to the robust clinical efficacy demonstrated in various trials for both tardive dyskinesia and Huntington's disease chorea."

Clinical Implications

This breakthrough in VMAT2 occupancy is significant because VMAT2 inhibition is a well-established therapeutic target for treating hyperkinetic movement disorders. By ensuring more potent engagement with VMAT2, drugs like INGREZZA could potentially lead to improved patient outcomes, especially in those suffering from the debilitating effects of tardive dyskinesia and chorea.

The data presented not only reflects superior efficacy but also opens the door for further research into the pharmacokinetic modeling of both drugs, which could detail how the body breaks down and responds to these treatments over time. This understanding may further enhance therapeutic strategies moving forward.

Safety Profile

Importantly, both INGREZZA and AUSTEDO XR showed favorable safety profiles, consistent with prior knowledge, and were well-tolerated by participants in the study. The evaluation of side effects is critical, as both medications aim to minimize adverse outcomes while maximizing efficacy.

Conclusion

The recent revelations about INGREZZA's higher VMAT2 target occupancy compared to AUSTEDO XR may significantly influence treatment protocols for movement disorders in the future. As Neurocrine Biosciences continues its efforts in addressing the unmet needs of patients suffering from these debilitating conditions, the implications of this data could lead to refined treatment options that enhance quality of life for those affected by tardive dyskinesia and Huntington's disease choreography. For further advancements in this field, ongoing studies and updates are anticipated, promising a hopeful future for patients requiring effective management of their symptoms.